Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 160

1.

A randomized study of tenofovir disoproxil fumarate in treatment-experienced HIV-1 infected adolescents.

Della Negra M, de Carvalho AP, de Aquino MZ, da Silva MT, Pinto J, White K, Arterburn S, Liu YP, Enejosa JV, Cheng AK, Chuck SL, Rhee MS.

Pediatr Infect Dis J. 2012 May;31(5):469-73. doi: 10.1097/INF.0b013e31824bf239.

PMID:
22301477
2.

Tenofovir disoproxil fumarate in nucleoside-resistant HIV-1 infection: a randomized trial.

Squires K, Pozniak AL, Pierone G Jr, Steinhart CR, Berger D, Bellos NC, Becker SL, Wulfsohn M, Miller MD, Toole JJ, Coakley DF, Cheng A; Study 907 Team.

Ann Intern Med. 2003 Sep 2;139(5 Pt 1):313-20.

PMID:
12965939
3.

Extended treatment with tenofovir disoproxil fumarate in treatment-experienced HIV-1-infected patients: genotypic, phenotypic, and rebound analyses.

Margot NA, Isaacson E, McGowan I, Cheng A, Miller MD.

J Acquir Immune Defic Syndr. 2003 May 1;33(1):15-21.

PMID:
12792350
4.

Long-term efficacy and safety of tenofovir disoproxil fumarate in HIV-1-infected adolescents failing antiretroviral therapy: the final results of study GS-US-104-0321.

Della Negra M, De Carvalho AP, De Aquino MZ, Pinto JA, Da Silva MT, Andreatta KN, Graham B, Liu YP, Quirk EK.

Pediatr Infect Dis J. 2015 Apr;34(4):398-405. doi: 10.1097/INF.0000000000000649.

PMID:
25599284
5.

Tenofovir DF in antiretroviral-experienced patients: results from a 48-week, randomized, double-blind study.

Schooley RT, Ruane P, Myers RA, Beall G, Lampiris H, Berger D, Chen SS, Miller MD, Isaacson E, Cheng AK; Study 902 Team.

AIDS. 2002 Jun 14;16(9):1257-63.

PMID:
12045491
6.

Efficacy and safety of tenofovir double-dose in treatment-experienced HIV-infected patients: the TENOPLUS study.

Dominguez S, Ghosn J, Peytavin G, Izzedine H, Wirden M, Ktorza N, Miller M, Aubron-Olivier C, Trylesinski A, Calvez V, Deray G, Katlama C.

J Med Virol. 2007 Feb;79(2):105-10.

PMID:
17177308
7.

Observational study on HIV-infected subjects failing HAART receiving tenofovir plus didanosine as NRTI backbone.

Bongiovanni M, Gianotti N, Chiesa E, Nasta P, Cicconi P, Capetti A, di Biagio A, Matti A, Tirelli V, Marconi P, de Luca A, Mussini C, Gatti F, Zaccarelli M, Abeli C, Torti C, Antinori A, Castagna A, d'Arminio Monforte A.

Infection. 2007 Dec;35(6):451-6. Epub 2007 Nov 21.

PMID:
18034204
8.

Antiretroviral efficacy and virological profile of a zidovudine/lamivudine/tenofovir disoproxil fumarate combination therapy in antiretroviral-naive patients.

Masquelier B, Neau D, Boucher S, Lavignolle-Aurillac V, Schrive MH, Recordon-Pinson P, Ragnaud JM, Fleury H.

Antivir Ther. 2006;11(6):827-30.

PMID:
17310827
9.

Salvage therapy with atazanavir/ritonavir combined to tenofovir in HIV-infected patients with multiple treatment failures: randomized ANRS 107 trial.

Piketty C, Gérard L, Chazallon C, Marcelin AG, Clavel F, Taburet AM, Calvez V, Madelaine-Chambrin I, Molina JM, Aboulker JP, Girard PM; Agence Nationale de Recherche sur le SIDA 107-Puzzle 2 Study Group.

Antivir Ther. 2006;11(2):213-21.

PMID:
16640102
10.

Long-term renal safety of tenofovir disoproxil fumarate in antiretroviral-naive HIV-1-infected patients. Data from a double-blind randomized active-controlled multicentre study.

Izzedine H, Hulot JS, Vittecoq D, Gallant JE, Staszewski S, Launay-Vacher V, Cheng A, Deray G; Study 903 Team.

Nephrol Dial Transplant. 2005 Apr;20(4):743-6. Epub 2005 Mar 1.

11.

Virologic response of zidovudine, lamivudine, and tenofovir disoproxil fumarate combination in antiretroviral-naive HIV-1-infected patients.

Rey D, Krebs M, Partisani M, Hess G, Cheneau C, Priester M, Bernard-Henry C, de Mautort E, Lang JM.

J Acquir Immune Defic Syndr. 2006 Dec 15;43(5):530-4.

PMID:
17057610
12.

Resistance profiles of emtricitabine and lamivudine in tenofovir-containing regimens.

Marcelin AG, Charpentier C, Wirden M, Landman R, Valantin MA, Simon A, Katlama C, Yeni P, Descamps D, Aubron-Olivier C, Calvez V.

J Antimicrob Chemother. 2012 Jun;67(6):1475-8. doi: 10.1093/jac/dks047. Epub 2012 Feb 26.

13.

In utero exposure to tenofovir disoproxil fumarate does not impair growth and bone health in HIV-uninfected children born to HIV-infected mothers.

Viganò A, Mora S, Giacomet V, Stucchi S, Manfredini V, Gabiano C, Salvini F, Cellini M, Tamburrini E, Puzzovio M, Zuccotti GV.

Antivir Ther. 2011;16(8):1259-66. doi: 10.3851/IMP1909.

PMID:
22155907
14.

The 3-year renal safety of a tenofovir disoproxil fumarate vs. a thymidine analogue-containing regimen in antiretroviral-naive patients.

Gallant JE, Winston JA, DeJesus E, Pozniak AL, Chen SS, Cheng AK, Enejosa JV.

AIDS. 2008 Oct 18;22(16):2155-63. doi: 10.1097/QAD.0b013e3283112b8e.

PMID:
18832879
15.

Nevirapine versus atazanavir/ritonavir, each combined with tenofovir disoproxil fumarate/emtricitabine, in antiretroviral-naive HIV-1 patients: the ARTEN Trial.

Soriano V, Arastéh K, Migrone H, Lutz T, Opravil M, Andrade-Villanueva J, Antunes F, Di Perri G, Podzamczer D, Taylor S, Domingo P, Gellermann H, de Rossi L; ARTEN investigators.

Antivir Ther. 2011;16(3):339-48. doi: 10.3851/IMP1745.

PMID:
21555816
16.

Determining the antiviral activity of tenofovir disoproxil fumarate in treatment-naive chronically HIV-1-infected individuals.

Louie M, Hogan C, Hurley A, Simon V, Chung C, Padte N, Lamy P, Flaherty J, Coakley D, Di Mascio M, Perelson AS, Markowitz M.

AIDS. 2003 May 23;17(8):1151-6.

PMID:
12819516
17.

Antiviral efficacy and genotypic resistance patterns of combination therapy with stavudine/tenofovir in highly active antiretroviral therapy experienced patients.

Antinori A, Trotta MP, Nasta P, Bini T, Bonora S, Castagna A, Zaccarelli M, Quirino T, Landonio S, Merli S, Tozzi V, Di Perri G, Andreoni M, Perno CF, Carosi G.

Antivir Ther. 2006;11(2):233-43.

PMID:
16640104
18.

Early virologic nonresponse to tenofovir, abacavir, and lamivudine in HIV-infected antiretroviral-naive subjects.

Gallant JE, Rodriguez AE, Weinberg WG, Young B, Berger DS, Lim ML, Liao Q, Ross L, Johnson J, Shaefer MS; ESS30009 Study.

J Infect Dis. 2005 Dec 1;192(11):1921-30. Epub 2005 Oct 25.

19.

Randomized, phase 2 evaluation of two single-tablet regimens elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate versus efavirenz/emtricitabine/tenofovir disoproxil fumarate for the initial treatment of HIV infection.

Cohen C, Elion R, Ruane P, Shamblaw D, DeJesus E, Rashbaum B, Chuck SL, Yale K, Liu HC, Warren DR, Ramanathan S, Kearney BP.

AIDS. 2011 Mar 27;25(6):F7-12. doi: 10.1097/QAD.0b013e328345766f.

PMID:
21412057
20.

[Clinical data I. Clinical experience with tenofovir in combination with nonnucleoside analogue transcriptase inhibitors].

Bernardino de la Serna JI, Mora Rillo M, Arribas López JR.

Enferm Infecc Microbiol Clin. 2008 Jun;26 Suppl 8:7-12. Review. Spanish.

PMID:
19195432
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk